Infectious complications and misuse of high-dose buprenorphine;Complications infectieuses et mésusage de la buprénorphine à haut dosage

Presse Medicale

Volumn 34, Issue 10, 2005, Pages 719-724

  Cazorla, C ^a   Grenier De Cardenal, D ^a   Schuhmacher, H ^a   Thomas, L ^a   Wack, A ^a   May, T ^a   Rabaud, Christian ^a,b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DIAMORPHINE;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; BONE INFECTION; CANDIDA RETINITIS; CLINICAL ARTICLE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG MISUSE; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; HEROIN DEPENDENCE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS ARTHRITIS; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ABUSE; MAINTENANCE THERAPY; MALE; MENINGITIS; PHARMACIST; PHYSICIAN; RETINITIS; RISK BENEFIT ANALYSIS; SEX RATIO; SKIN ABSCESS; SOCIAL PSYCHOLOGY; SYSTEMIC DISEASE; TEAMWORK; UNIVERSITY HOSPITAL; VIRUS HEPATITIS;

EID: 20944433604     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84025-4     Document Type: Article

References (27)

1. Decocq G, Fremaux D, Smail A. Complications locales après injection intraveineuse de comprimés dissous de buprénorphine. Presse Med 1997; 26: 1433.
2. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opioate dependence. Addiction 2001; 96: 683-90.
3. Vidal-Trecan G, Boissonnas A, Varescon I. Usagers de drogues injectables et buprénorphine haut dosage. Analyse des déviations de son utilisation. Paris: OFDT, 2000, 51p.
4. Tracqui A, Fonmartin K, Kintz P. Narcotic related fatalities investigated at the medico-legal institute of Strasbourg, France: 302 observations (1991-1997). Journal de Médecine Legale Droit Médical 1999; 1: 3-10.
5. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinationswhy the 4:1 ratio for treatment? Drug Alcohol Depend 2003; 70 Suppl 2: S29-S37.
6. Tracqui A, Tournoud C, Flesch F. Intoxications aiguës par traitement substitutif à base de buprénorphine haut dosage. Presse Med 1998; 27: 557-61.
7. Tacke U. Abuse of buprenorphine by intravenous injection - The French connection. Addiction 2001; 97: 1355.
8. Fontaa V, Bronner C. Persistent injecting practices in subjects on methadone on buprenorphine maintenance therapy. A study of 600 cases. Ann Med Int 2001; 152 Suppl 7: 59-69.
9. Fhima A, Henrion R, Lowenstein W, Charpak Y. Suivi à deux ans d'une cohorte de patients dépendants aux opiacés traités par buprénorphine haut dosage (Subutex®). Ann Med Int 2001; 152 Suppl 3: 1S26-1S36.
10. Morel A. Traitements de substitution à la buprénorphine: l'expérience française. Toxibase 2000; 3: 1-37.
11. Thirion X, Barrau K, Micallef J, Haramburu F, Lowenstein W, Sanmarco JL Traitements de substitution de la dépendance aux opiacés dans les centres de soins: le programme OPPIDUM des Centres d'Evaluation et d'Information sur la Pharmacodépendance. Ann Med Int 2000; 151 Suppl A: 10-17.
12. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003; 69: 175-81.
13. Bennett JE, Mandell GL, Dolin R. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 5th edition. Edinburg: Churchill Livingstone 2000-3536p.
14. Hoen B, Alla F, Selton-Suty C, Beguinot I, Bouvet A, Briancon S et al. Changing profile of infective endocarditis. Result of 1-year survey in France. JAMA 2002; 288: 75-81.
15. Brown PD, Levine DP. Infective endocarditis in the injection drug user. Infect Dis North Am 2002; 16: 645-65.
16. Seghatol F, Grinberg I. Left-sided endocarditis in intravenous drug users: a case report and review of the literature. Echoardiography 2002; 19: 509-11.
17. Toufik A, Sarradet A, Gandilhon M. Tendances récentes. Rapport TREND. Paris: OFDT, 2000: 99p.
18. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001; 345: 1318-30.
19. Cohen A, Belmatoug N. Cœur et médecine interne. Paris: ESTEM, 2002-2 vol, 2309p.
20. Olaison L, Petterson G. Current best practices and guidelines indications for surgical intervention in infective endocarditis. Infect Dis Clin N Am 2002; 16: 453-75.
21. Mouzon S. Candidoses disséminées à Candida albicans chez les toxicomanes, dont injecteurs de Subutex® (buprénorphine haut dosage) en comprimés sublingual. Th: Méd: Reims: 2001; M042.
22. Duburcq A, Charpak Y, Blin P, Madec L Suivi à deux ans d'une cohorte de patients sous buprénorphine haut dosage. Résultats de l'étude Spesub (suivi pharmaco-épidémiologique du Subutex® en médecine de ville. Rev Epidem et Santé Publ 2000; 48: 363-73.
23. Lavignasse P, Lowenstein W, Batel P, Constant MV, Jourdain JJ, Kopp P, Reynaud-Maurupt C et al. Economic and social effects of high-dose buprenorphine substitution therapy. Ann Med Int 2002; 153; Suppl 3: 1520-1526.
24. Lepère D, Gourarier L, Sanchez M. Diminution du nombre de surdoses mortelles à l'héroïne, en France, depuis 1994. Ann Med Int 2001; 152 Suppl 3: 155-1512.
25. Thirion X, Lapierre V, Micaleff J. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 2002; 65: 197-204.
26. Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opiod-dependent humans. Drug Alcohol Depend 2001; 61: 173-81.
27. Gross A, Jacobs EA, Petry NM, Badger GJ, Bickel WK. Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days. Drug Alcohol Depend 2001; 64: 111-16.